샘플 요청 목록

 카트 문의
시장보고서
상품코드
1798224

재조합 백신 시장

Recombinant Vaccines
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 383 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 재조합 백신 시장은 2030년까지 191억 달러에 이를 전망

2024년에 109억 달러로 추정되는 재조합 백신 세계 시장은 2024-2030년간 CAGR 9.8%로 성장하여 2030년에는 191억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 아단위 재조합 백신은 CAGR 8.3%를 나타내고, 분석 기간 종료까지 106억 달러에 이를 것으로 예측됩니다. Attenuated 재조합 백신 부문의 성장률은 분석 기간중 CAGR 12.4%로 추정됩니다.

미국 시장은 30억 달러로 추정, 중국은 CAGR13.2%로 성장 예측

미국의 재조합 백신 시장은 2024년에 30억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 38억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 13.2%로 추정됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 7.2%와 8.6%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 7.7%를 보일 전망입니다.

세계의 재조합 백신 시장 - 주요 동향과 촉진요인 정리

재조합 기술은 백신 개발 및 전달을 어떻게 재정의하고 있는가?

유전자 재조합 백신 플랫폼은 유전공학을 활용하여 특이성이 높고 안정적이고 안전한 백신 항원을 제조할 수 있게 함으로써 전 세계 예방접종 사정에 혁명을 일으켰습니다. 기존의 불활성화 백신이나 약독화 백신과 달리 재조합 백신은 효모, 세균, 포유류 등의 숙주 세포에서 선택적 항원의 발현에 의존하여 병원체의 재 활성화 및 오염의 위험을 최소화합니다. 이 기술은 HPV, B형 간염, 대상포진 등 기존 백신이 장기적인 효과와 안전성을 확보하지 못한 질환에 대한 채택이 증가하고 있습니다. 또한, 재조합 플랫폼의 유연성은 신종 병원체에 대한 신속한 대응을 가능케 하여 전염병 대응 및 확산 억제 전략에 필수적인 요소로 작용하고 있습니다.

코로나 이후 재조합 DNA 기술, 특히 mRNA와 호환되는 구조물이나 유전물질 없이 원래의 바이러스를 모방하는 바이러스 유사 입자(VLP)에 대한 관심이 가속화되고 있습니다. 세계 공중보건 이니셔티브는 저자원 환경에서 백신에 대한 접근성과 접종률을 높이기 위해 내열성, 무침, 보조제 강화형 재조합 제제 개발에 우선순위를 두고 있습니다. 이와 함께, 재조합 백신은 특히 항원 특이성과 면역 조절이 가장 중요한 종양학 및 알레르겐 감작에서 개인 맞춤형 면역 전략의 중심이 되고 있습니다. 연구개발 파이프라인이 확대됨에 따라 재조합 백신 개발은 예방 및 치료용 백신의 주류를 점점 더 차지할 것으로 예측됩니다.

어떤 질병 부문과 대상 집단이 채택을 주도하고 있는가?

간염, 인간유두종바이러스(HPV), 호흡기세포융합바이러스(RSV), 독감 분야에서 재조합 백신의 기세가 가장 강합니다. 특히 동남아시아 및 사하라 사막 이남 아프리카에서는 국가 예방접종 프로그램에 재조합 B형 간염 백신이 광범위하게 채택되어 만성 감염과 그에 따른 간암이 크게 감소하고 있습니다. 학교 기반 프로그램에 HPV 백신이 포함되면서 청소년과 젊은 성인들의 재조합 백신 사용이 촉진되고 있습니다. 또한, 고령자 및 임산부를 위한 RSV 백신의 도입은 특히 재조합형 제제의 도입으로 생애주기별 예방접종 접근법의 중요성이 증가하고 있음을 보여줍니다.

소아 집단, 면역결핍자, 노인 인구는 유전자 재조합 백신의 우선 접종 대상자로 부상하고 있습니다. 이들 집단은 우수한 안전성 프로파일과 부작용 위험 감소로 인해 재조합 제제의 혜택을 누리고 있습니다. 또한, 재조합 종양 관련 항원을 이용한 종양 백신이 빠르게 임상 개발되고 있어 치료 적용으로의 전환을 시사하고 있습니다. 민관 협력, GAVI의 지원, WHO의 사전 승인으로 재조합 백신이 개발도상국의 정기 예방접종 일정에 포함되고 있습니다. 전 세계 백신 접종 전략이 어린 시절에 초점을 맞춘 것에서 진화함에 따라, 재조합 백신은 항균제 내성 감소 및 암 예방과 같은 보다 광범위한 공중 보건 목표를 달성할 준비가 되어 있습니다.

주요 공급망 및 규제적 지원 요인은 무엇인가?

제조의 확장성과 공정 관리는 재조합 백신의 성공적인 상용화를 위해 필수적입니다. 기존의 계란 기반 방식과 달리 재조합 플랫폼은 보다 예측 가능한 수율, 생산 기간 단축, 생물학적 안전성 강화를 제공합니다. 주요 제조업체는 일회용 바이오리액터 시스템, 자동 정제 공정, 콜드체인 혁신에 투자하고 전 세계 유통을 지원하고 있습니다. 또한, 재조합 백신 제조의 모듈화된 특성은 새로운 질병 표적에 빠르게 적응할 수 있는 다병원성 플랫폼을 가능하게 하여 미래의 건강 위기에 대한 회복력을 뒷받침하고 있습니다.

규제 측면에서 재조합 백신은 미국 FDA, EMA 및 수요가 높은 예방접종 제품을 우선시하는 세계 규제 기관에서 가속화된 경로의 혜택을 누리고 있습니다. 재조합 백신이 WHO의 긴급 사용 목록에 등재됨에 따라 각국의 신속한 승인과 함께 발병 시 신속한 배포를 위한 길이 열리고 있습니다. 또한, 약물감시 프레임워크와 시판 후 조사에서 얻은 실제 증거는 재조합 제제의 안전성과 유효성 프로파일을 지속적으로 강화하고 있습니다. CDMO(위탁 개발 및 제조 기관)와의 제휴는 생명공학 혁신가들이 세계 수요 증가에 대응하기 위해 재조합 백신의 생산량을 확대할 수 있도록 역량 격차를 해소하는 데 큰 도움이 되고 있습니다.

이 시장의 지속적인 성장 원동력은 무엇인가?

재조합 백신 시장의 성장 원동력은 몇 가지 요인이 있습니다. 특히, 정밀 예방접종에 대한 전 세계적인 관심 증가, 생애주기에 따른 예방접종 전략의 확대, 백신으로 예방 가능한 질병의 발생률 증가 등을 꼽을 수 있습니다. 의료 시스템이 예방접종 프로그램의 효과, 안전성, 접근성을 개선하기 위해 노력하고 있는 가운데, 재조합 기술은 과학적으로 검증되고 상업적으로 확장 가능한 솔루션을 제공합니다. 전 연령층에 대한 보편적 백신 접종으로의 전환은 정부 및 기부 기관의 지원과 함께 일상적인 예방접종과 발병 시 대응 모두에서 수요를 가속화하고 있습니다.

기술 혁신 또한 성장의 큰 기폭제가 되고 있습니다. 재조합 단백질 발현, 나노입자 전달 시스템, 열 안정화 기술의 발전으로 농촌 지역이나 의료 서비스를 받지 못하는 지역에도 백신이 보급되고 있습니다. 차세대 보조제 및 점막 투여법에 대한 지속적인 투자로 재조합 백신의 면역원성 및 환자 수용성이 더욱 향상되고 있습니다. 또한, 코로나19 mRNA 백신의 성공은 재조합 플랫폼에 대한 전 세계의 신뢰를 높이고, 신종 감염병 및 암 퇴치에 대한 가능성을 확인시켜 주었습니다.

제약회사들이 지속가능한 백신 생산과 공평한 접근을 우선시하는 가운데, 재조합 백신 기술은 미래를 대비하는 예방접종 생태계의 중추가 되고 있습니다. 새로운 적응증, 광범위한 규제 당국의 지원, 중진국에서의 헬스케어 투자 증가로 인해 시장 확대는 더욱 가속화될 것으로 예측됩니다.

부문

백신 유형(아단위, 급성화, 벡터), 질환(폐렴구균, 암, B형 간염, 인플루엔자, DPT, 기타 질환), 유통 채널(병원 및 소매 약국, 정부 공급업체)

조사 대상 기업 예

  • AbbVie Inc.
  • AstraZeneca plc
  • Bavarian Nordic
  • Bharat Biotech
  • Clover Biopharmaceuticals
  • CSL Limited
  • Dynavax Technologies Corporation
  • Emergent BioSolutions
  • GlaxoSmithKline plc(GSK)
  • Green Cross Corporation(GC Biopharma)
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Panacea Biotec
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vaxart, Inc.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.09.03

Global Recombinant Vaccines Market to Reach US$19.1 Billion by 2030

The global market for Recombinant Vaccines estimated at US$10.9 Billion in the year 2024, is expected to reach US$19.1 Billion by 2030, growing at a CAGR of 9.8% over the analysis period 2024-2030. Subunit Recombinant Vaccines, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$10.6 Billion by the end of the analysis period. Growth in the Attenuated Recombinant Vaccines segment is estimated at 12.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 13.2% CAGR

The Recombinant Vaccines market in the U.S. is estimated at US$3.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.8 Billion by the year 2030 trailing a CAGR of 13.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.2% and 8.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.7% CAGR.

Global Recombinant Vaccines Market - Key Trends & Drivers Summarized

How Are Recombinant Technologies Redefining Vaccine Development and Delivery?

Recombinant vaccine platforms have revolutionized the global immunization landscape by enabling the production of highly specific, stable, and safe vaccine antigens using genetic engineering. Unlike traditional inactivated or live-attenuated vaccines, recombinant vaccines rely on the expression of select antigens in host cells such as yeast, bacteria, or mammalian systems, minimizing the risk of pathogen reactivation or contamination. This technology is increasingly adopted for diseases where traditional vaccines have failed to deliver long-term efficacy or safety, including HPV, hepatitis B, and shingles. Moreover, the flexibility of recombinant platforms allows for rapid response to emerging pathogens, making them vital in pandemic preparedness and outbreak containment strategies.

The post-COVID era has ushered in an acceleration of interest in recombinant DNA technologies, particularly in mRNA-compatible constructs and virus-like particles (VLPs) that mimic native viruses without carrying genetic material. Global public health initiatives are prioritizing the development of thermostable, needle-free, and adjuvant-enhanced recombinant formulations to boost vaccine access and coverage in low-resource settings. In parallel, recombinant vaccines are becoming central to personalized immunization strategies, especially in oncology and allergen desensitization, where antigen specificity and immune modulation are paramount. As R&D pipelines expand, recombinant vaccine development is expected to increasingly dominate the prophylactic and therapeutic vaccine landscape.

Which Disease Segments and Target Populations Are Driving Adoption?

The strongest momentum for recombinant vaccines is being observed in hepatitis, human papillomavirus (HPV), respiratory syncytial virus (RSV), and influenza segments. Widespread adoption of recombinant hepatitis B vaccines in national immunization programs, especially in Southeast Asia and Sub-Saharan Africa, has significantly reduced chronic infections and associated liver cancers. The inclusion of HPV vaccines in school-based programs is propelling recombinant vaccine usage among adolescents and young adults. Additionally, RSV vaccine rollouts for older adults and pregnant women-especially with the introduction of recombinant formulations-highlight the growing importance of life-course immunization approaches.

Pediatric populations, immunocompromised individuals, and geriatrics are emerging as high-priority targets for recombinant vaccine delivery. These groups benefit from recombinant formulations due to their superior safety profiles and reduced risk of adverse events. Furthermore, oncology vaccines leveraging recombinant tumor-associated antigens are under rapid clinical development, signaling a shift toward therapeutic applications. Public-private partnerships, GAVI support, and WHO prequalification are catalyzing recombinant vaccine inclusion in routine immunization schedules in developing countries. As global vaccination strategies evolve beyond childhood focus, recombinant vaccines are poised to address broader public health goals, including antimicrobial resistance reduction and cancer prevention.

What Are the Key Supply Chain and Regulatory Enablers?

Manufacturing scalability and process control are essential to the success of recombinant vaccine commercialization. Unlike traditional egg-based methods, recombinant platforms offer more predictable yields, reduced production timelines, and enhanced biosafety. Leading manufacturers are investing in single-use bioreactor systems, automated purification processes, and cold chain innovations to support global distribution. Additionally, the modular nature of recombinant vaccine production allows for multi-pathogen platforms that can be swiftly adapted to new disease targets, supporting resilience in future health crises.

From a regulatory standpoint, recombinant vaccines are benefitting from accelerated pathways in the U.S. FDA, EMA, and global regulatory bodies that prioritize high-need immunization products. The inclusion of recombinant vaccines in WHO’s emergency use listings, alongside expedited national licensing, is paving the way for rapid deployment during outbreaks. Moreover, pharmacovigilance frameworks and real-world evidence from post-marketing surveillance are continuously reinforcing the safety and efficacy profiles of recombinant products. Partnerships with contract development and manufacturing organizations (CDMOs) are further helping biotech innovators bridge capability gaps and scale recombinant vaccine production to meet growing global demand.

What Is Fueling the Sustained Growth of This Market?

The growth in the recombinant vaccines market is driven by several factors, most notably the increasing global focus on precision immunization, the expansion of life-course vaccination strategies, and the rising incidence of vaccine-preventable diseases. As healthcare systems seek to improve the efficacy, safety, and accessibility of immunization programs, recombinant technologies offer a scientifically validated and commercially scalable solution. The shift toward universal vaccination across all age groups, combined with governmental and donor agency support, is accelerating demand in both routine and outbreak response settings.

Technological innovation is also a major growth catalyst. Advancements in recombinant protein expression, nanoparticle delivery systems, and thermostabilization techniques are extending the reach of vaccines to rural and underserved areas. Continued investment in next-generation adjuvants and mucosal delivery methods is further enhancing the immunogenicity and patient acceptability of recombinant vaccines. Furthermore, the success of COVID-19 mRNA vaccines has increased global trust in recombinant platforms and validated their potential in combating emerging infectious diseases and cancer.

As pharmaceutical companies prioritize sustainable vaccine production and equitable access, recombinant vaccine technologies are becoming the backbone of future-ready immunization ecosystems. Market expansion is expected to intensify with new indications, broader regulatory support, and rising healthcare investments across middle-income nations.

SCOPE OF STUDY:

The report analyzes the Recombinant Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vaccine Type (Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines, Vector Recombinant Vaccines); Disease (Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease, Other Diseases); Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • AbbVie Inc.
  • AstraZeneca plc
  • Bavarian Nordic
  • Bharat Biotech
  • Clover Biopharmaceuticals
  • CSL Limited
  • Dynavax Technologies Corporation
  • Emergent BioSolutions
  • GlaxoSmithKline plc (GSK)
  • Green Cross Corporation (GC Biopharma)
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Panacea Biotec
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vaxart, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Recombinant Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Global Focus on Pandemic Preparedness Throws the Spotlight on Recombinant Vaccine Technologies
    • Surging Demand for Safe and Stable Vaccines Propels Growth in Recombinant Vaccine Adoption
    • Rising Incidence of Zoonotic and Emerging Infectious Diseases Drives Innovation in Recombinant Platforms
    • Rapid Antigen Design Capabilities Strengthen Business Case for Recombinant DNA and Protein Vaccines
    • Success of mRNA and Recombinant COVID-19 Vaccines Expands Addressable Market for Advanced Platforms
    • Cost-Effective Manufacturing and Scalability Spur Demand for Recombinant Vaccine Technologies
    • Expansion of Veterinary and Aquaculture Immunization Programs Generates Demand for Recombinant Vaccines
    • Global Immunization Campaigns Supported by WHO and GAVI Accelerate Adoption of Recombinant Products
    • Cross-Platform Compatibility With Adjuvants and Vectors Enhances Flexibility of Recombinant Vaccine Development
    • Rise in Travel-Associated Infections Spurs Demand for Broad-Spectrum Recombinant Vaccines
    • Advancements in Yeast, Bacterial, and Insect Cell Platforms Drive Diversification of Recombinant Pipelines
    • Increased Focus on Non-Invasive Delivery Systems Strengthens Business Case for Oral Recombinant Vaccines
    • Use of AI in Epitope Prediction and Antigen Design Expands Customization Opportunities in Recombinant Vaccines
    • R&D Partnerships Between Public Health Institutes and Biotech Firms Propel Recombinant Innovation
    • Growing Resistance to Traditional Vaccine Production Methods Supports Adoption of Recombinant Alternatives
    • Integration of Recombinant Antigens in Combination Vaccines Broadens Market Potential
    • Supportive Regulatory Pathways and Accelerated Approvals Expedite Recombinant Vaccine Commercialization
    • Increased Biodefense Funding by Governments Drives Pipeline Expansion for Recombinant Technologies
    • Adoption of Recombinant Flu Vaccines in National Programs Sustains Market Growth Momentum
    • Cold Chain Challenges in Remote Regions Strengthen Preference for Thermostable Recombinant Formulations
    • Surge in Consumer Preference for Non-Animal-Based Vaccines Enhances Market Receptivity
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recombinant Vaccines Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Recombinant Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Recombinant Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Recombinant Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Subunit Recombinant Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Subunit Recombinant Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Subunit Recombinant Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Attenuated Recombinant Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Attenuated Recombinant Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Attenuated Recombinant Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Vector Recombinant Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Vector Recombinant Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Vector Recombinant Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospital & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Government Suppliers Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Government Suppliers Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Government Suppliers Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pneumococcal Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Pneumococcal Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Pneumococcal Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Cancer Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Cancer Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Cancer Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hepatitis B Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hepatitis B Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Hepatitis B Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Influenza Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Influenza Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Influenza Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for DPT Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for DPT Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for DPT Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Recombinant Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • JAPAN
    • Recombinant Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • CHINA
    • Recombinant Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • EUROPE
    • Recombinant Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Recombinant Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Recombinant Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Recombinant Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • FRANCE
    • Recombinant Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • GERMANY
    • Recombinant Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Recombinant Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Recombinant Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Recombinant Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Recombinant Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Recombinant Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • INDIA
    • Recombinant Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: India 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Recombinant Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Recombinant Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Recombinant Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Recombinant Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Recombinant Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Recombinant Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Recombinant Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Recombinant Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
  • AFRICA
    • Recombinant Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제